AbbVie | ABBV - Gross Profit On Sales

Stock Price
224.69
Daily Change
-2.23 -0.98%
Monthly
0.34%
Yearly
9.59%
Q1 Forecast
217.84

AbbVie reported $10.47B in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Abbott USD 6.54B 625M Dec/2025
ALKERMES USD 338.34M 72.51M Dec/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Coherus Biosciences USD 4.95M 15.34M Mar/2025
Eisai JPY 168.85B 17.02B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Infinity Pharmaceuticals USD 231K 59K Jun/2023
J&J USD 16.6B 118M Dec/2025
Medtronic USD 5.41B 27M Dec/2025
Merck USD 13.42B 431M Sep/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Novartis USD 10.82B 695M Sep/2025
Pacira USD 142.25M 11.34M Dec/2025
Perrigo USD 362.2M 14.9M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 2.46B 520M Dec/2024
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
United Therapeutics USD 315.5M 286.6M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025
Zoetis USD 1.64B 73M Dec/2025